scholarly article | Q13442814 |
P356 | DOI | 10.1038/S41409-019-0662-6 |
P698 | PubMed publication ID | 31484991 |
P50 | author | Kyle R Brownback | Q88488742 |
Christopher Streiler | Q93106881 | ||
P2093 | author name string | Sunil Abhyankar | |
Christian Davis | |||
Faizan Shaikh | |||
P2860 | cites work | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report | Q35085226 |
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation | Q36712018 | ||
Diagnosis and manifestations of chronic graft-versus-host disease | Q37173472 | ||
Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial | Q38372551 | ||
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation | Q43579107 | ||
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease | Q49724160 | ||
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
Ruxolitinib is an effective steroid sparing agent in children with steroid refractory/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation | Q91229389 | ||
P921 | main subject | bronchiolitis | Q424227 |
bronchiolitis obliterans | Q614750 | ||
ruxolitinib | Q7383611 | ||
P577 | publication date | 2019-09-04 | |
P1433 | published in | Bone Marrow Transplantation | Q4941523 |
P1476 | title | Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease |
Search more.